Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

Mónica Alejandra Anaya-Segura, Froylan Arturo García-Martínez, Luis Ángel Montes-Almanza, Benjamín Gómez Díaz, Guillermina Ávila-Ramírez, Ikuri Alvarez-Maya, Ramón Mauricio Coral-Vázquez, Paul Mondragón-Terán, Rosa Elena Escobar-Cedillo, Noemí García-Calderón, Norma Alejandra Vázquez-Cardenas, Silvia García, Luz Berenice López-Hernández

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

© 2015 by the authors. Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid naïve patients and healthy controls of similar age and also for carrier detection. Our data suggest that serum levels of MMP-9, GDF-8 and FSTN are useful to discriminate DMD from controls (p
Original languageAmerican English
Pages (from-to)11154-11172
Number of pages19
JournalMolecules
DOIs
StatePublished - 1 Jun 2015

Fingerprint

Myostatin
Duchenne Muscular Dystrophy
biomarkers
Biomarkers
Follistatin
Matrix Metalloproteinase 9
serums
matrices
creatine
disabilities
steroids
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase 2
Creatine Kinase
progressions
inhibitors
Serum
Steroids
disorders
Disease Progression

Cite this

Anaya-Segura, M. A., García-Martínez, F. A., Montes-Almanza, L. Á., Díaz, B. G., Ávila-Ramírez, G., Alvarez-Maya, I., ... López-Hernández, L. B. (2015). Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules, 11154-11172. https://doi.org/10.3390/molecules200611154
Anaya-Segura, Mónica Alejandra ; García-Martínez, Froylan Arturo ; Montes-Almanza, Luis Ángel ; Díaz, Benjamín Gómez ; Ávila-Ramírez, Guillermina ; Alvarez-Maya, Ikuri ; Coral-Vázquez, Ramón Mauricio ; Mondragón-Terán, Paul ; Escobar-Cedillo, Rosa Elena ; García-Calderón, Noemí ; Vázquez-Cardenas, Norma Alejandra ; García, Silvia ; López-Hernández, Luz Berenice. / Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection. In: Molecules. 2015 ; pp. 11154-11172.
@article{fa285f59782f4105b7254419edb95095,
title = "Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection",
abstract = "{\circledC} 2015 by the authors. Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid na{\"i}ve patients and healthy controls of similar age and also for carrier detection. Our data suggest that serum levels of MMP-9, GDF-8 and FSTN are useful to discriminate DMD from controls (p",
author = "Anaya-Segura, {M{\'o}nica Alejandra} and Garc{\'i}a-Mart{\'i}nez, {Froylan Arturo} and Montes-Almanza, {Luis {\'A}ngel} and D{\'i}az, {Benjam{\'i}n G{\'o}mez} and Guillermina {\'A}vila-Ram{\'i}rez and Ikuri Alvarez-Maya and Coral-V{\'a}zquez, {Ram{\'o}n Mauricio} and Paul Mondrag{\'o}n-Ter{\'a}n and Escobar-Cedillo, {Rosa Elena} and Noem{\'i} Garc{\'i}a-Calder{\'o}n and V{\'a}zquez-Cardenas, {Norma Alejandra} and Silvia Garc{\'i}a and L{\'o}pez-Hern{\'a}ndez, {Luz Berenice}",
year = "2015",
month = "6",
day = "1",
doi = "10.3390/molecules200611154",
language = "American English",
pages = "11154--11172",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute",

}

Anaya-Segura, MA, García-Martínez, FA, Montes-Almanza, LÁ, Díaz, BG, Ávila-Ramírez, G, Alvarez-Maya, I, Coral-Vázquez, RM, Mondragón-Terán, P, Escobar-Cedillo, RE, García-Calderón, N, Vázquez-Cardenas, NA, García, S & López-Hernández, LB 2015, 'Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection', Molecules, pp. 11154-11172. https://doi.org/10.3390/molecules200611154

Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection. / Anaya-Segura, Mónica Alejandra; García-Martínez, Froylan Arturo; Montes-Almanza, Luis Ángel; Díaz, Benjamín Gómez; Ávila-Ramírez, Guillermina; Alvarez-Maya, Ikuri; Coral-Vázquez, Ramón Mauricio; Mondragón-Terán, Paul; Escobar-Cedillo, Rosa Elena; García-Calderón, Noemí; Vázquez-Cardenas, Norma Alejandra; García, Silvia; López-Hernández, Luz Berenice.

In: Molecules, 01.06.2015, p. 11154-11172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

AU - Anaya-Segura, Mónica Alejandra

AU - García-Martínez, Froylan Arturo

AU - Montes-Almanza, Luis Ángel

AU - Díaz, Benjamín Gómez

AU - Ávila-Ramírez, Guillermina

AU - Alvarez-Maya, Ikuri

AU - Coral-Vázquez, Ramón Mauricio

AU - Mondragón-Terán, Paul

AU - Escobar-Cedillo, Rosa Elena

AU - García-Calderón, Noemí

AU - Vázquez-Cardenas, Norma Alejandra

AU - García, Silvia

AU - López-Hernández, Luz Berenice

PY - 2015/6/1

Y1 - 2015/6/1

N2 - © 2015 by the authors. Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid naïve patients and healthy controls of similar age and also for carrier detection. Our data suggest that serum levels of MMP-9, GDF-8 and FSTN are useful to discriminate DMD from controls (p

AB - © 2015 by the authors. Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid naïve patients and healthy controls of similar age and also for carrier detection. Our data suggest that serum levels of MMP-9, GDF-8 and FSTN are useful to discriminate DMD from controls (p

U2 - 10.3390/molecules200611154

DO - 10.3390/molecules200611154

M3 - Article

C2 - 26091074

SP - 11154

EP - 11172

JO - Molecules

JF - Molecules

SN - 1420-3049

ER -

Anaya-Segura MA, García-Martínez FA, Montes-Almanza LÁ, Díaz BG, Ávila-Ramírez G, Alvarez-Maya I et al. Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules. 2015 Jun 1;11154-11172. https://doi.org/10.3390/molecules200611154